PROLONG Study

(Redirected from The PROLONG Study)
Jump to navigation Jump to search

D-Dimer Microchapters

Home

Patient information

Overview

Historical Perspective

Physiology

Clinical Correlation

Causes of High D-dimer

Diagnostic Role in Thromboembolism

Prognostic Role in Mortality

Prognostic Role in Thromboembolism Occurence

Prognostic Role in Thromboembolism Recurrence

Prognostic Role in Non-Thromboembolism

Clinical Trials

Landmark Trials

Case #1

PROLONG Study On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of PROLONG Study

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on PROLONG Study

CDC on PROLONG Study

PROLONG Study in the news

Blogs on PROLONG Study

Directions to Hospitals Treating D-dimer

Risk calculators and risk factors for PROLONG Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Official Title

D-Dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized “Prolong” Study

Objective

The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain. The present study addresses the possible role of the D-dimer test in assessing the need for continuation of anticoagulation. The study aims at assessing whether D-dimer assay may have a role in guiding the duration of anticoagulation in these patients.

St. Orsola Hospital

Timeline

Timeline
Start Date September 2002
End Date Not provided
Status Completed

The previous information was derived from ClinicalTrials.gov on 09/25/2013 using the identification number NCT00264277.

Study Description

Study Description
Study Type Interventional
Study Phase Phase 4
Study Design
Allocation Randomised
Endpoint Safety/Efficacy Study
Interventional Model Parallel Assignment
Masking Open Label
Study Details
Primary Purpose Treatment
Condition Deep Vein Thrombosis
Pulmonary Embolism
Intervention Vitamin K antagonist (Coumarin anticoagulants)
Study Arms Not provided
Population Size 600

The previous information was derived from ClinicalTrials.gov on 09/25/2013 using the identification number NCT00264277.

Eligibility Criteria

Inclusion Criteria

  • Age > 18 years
  • After a first documented idiopathic proximal deep vein thrombosis and/or pulmonary embolism
  • After at least 3 months of oral anticoagulation
  • After written informed consent

Exclusion Criteria

  • If the Venous thromboembolism occurred:
    • During pregnancy or puerperium
    • After recent (i.e. within three months) fracture or plaster casting of a leg,
    • After immobilization with confinement to bed for three consecutive days
    • After surgery with general anesthesia lasting longer than 30 minutes
  • Patients with:
    • Active cancer
    • Antiphospholipid antibody syndrome
    • Antithrombin deficiency
    • Serious liver disease or renal insufficiency (creatininemia > 2 mg/dL),
    • Other indications for anticoagulation or contraindications for this treatment
    • Limited life expectation
  • Patients who live too far from the clinical center


Outcomes

Primary Outcomes

  • Confirmed recurrent proximal deep vein thrombosis and/or pulmonary embolism at 18 months follow up
  • Confirmed major bleeding events at 18 months follow up

Secondary Outcomes

Not provided

Publications

Results

Conclusion

References

Template:WH Template:WS